# PRA Group Inc: financial statements, quarterly

PRAA · Nasdaq · CIK 1185348 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/praa.md) · [Financials](/companies/praa/financials.md) · [Filings](/companies/praa/filings.md) · [Insiders](/companies/praa/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/praa/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [216](/filings/0001185348-24-000052.md) | [221 d](/filings/0001185348-26-000006.md) | [256](/filings/0001185348-25-000012.md) | [284](/filings/0001185348-25-000022.md) | [281](/filings/0001185348-25-000043.md) | [293 d](/filings/0001185348-26-000006.md) | [270](/filings/0001185348-26-000021.md) | [288](/filings/0001185348-26-000028.md) | [311](/filings/0001185348-25-000043.md) | [333 d](/filings/0001185348-26-000006.md) | [315](/filings/0001185348-26-000021.md) | [372](/filings/0001185348-26-000028.md) |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [43.0](/filings/0001185348-24-000052.md) | [45.5 d](/filings/0001185348-26-000006.md) | [66.4](/filings/0001185348-25-000012.md) | [89.2](/filings/0001185348-25-000022.md) | [90.0](/filings/0001185348-25-000043.md) | [94.1 d](/filings/0001185348-26-000006.md) | [74.6](/filings/0001185348-26-000021.md) | [85.1](/filings/0001185348-26-000028.md) | [(316)](/filings/0001185348-25-000043.md) | [126 d](/filings/0001185348-26-000006.md) | [103](/filings/0001185348-26-000021.md) | [153](/filings/0001185348-26-000028.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [1.8](/filings/0001185348-24-000052.md) | [(0.8) d](/filings/0001185348-26-000006.md) | [2.4](/filings/0001185348-25-000012.md) | [8.7](/filings/0001185348-25-000022.md) | [(0.7)](/filings/0001185348-25-000043.md) | [10.6 d](/filings/0001185348-26-000006.md) | [4.3](/filings/0001185348-26-000021.md) | [15.4](/filings/0001185348-26-000028.md) | [24.4](/filings/0001185348-25-000043.md) | [2.6 d](/filings/0001185348-26-000006.md) | [8.8](/filings/0001185348-26-000021.md) | [29.4](/filings/0001185348-26-000028.md) |
| Net income | $m | [(12.3)](/filings/0001185348-24-000052.md) | [(8.8) d](/filings/0001185348-26-000006.md) | [3.5](/filings/0001185348-25-000012.md) | [21.5](/filings/0001185348-25-000022.md) | [27.2](/filings/0001185348-25-000043.md) | [18.5 d](/filings/0001185348-26-000006.md) | [3.7](/filings/0001185348-26-000021.md) | [42.4](/filings/0001185348-26-000028.md) | [(408)](/filings/0001185348-25-000043.md) | [56.5 d](/filings/0001185348-26-000006.md) | [28.2](/filings/0001185348-26-000021.md) | [57.9](/filings/0001185348-26-000028.md) |
| Diluted EPS | $ per share | [(0.31)](/filings/0001185348-24-000052.md) | not reported | [0.09](/filings/0001185348-25-000012.md) | [0.54](/filings/0001185348-25-000022.md) | [0.69](/filings/0001185348-25-000043.md) | not reported | [0.09](/filings/0001185348-26-000021.md) | [1.08](/filings/0001185348-26-000028.md) | [(10.43)](/filings/0001185348-25-000043.md) | not reported | [0.73](/filings/0001185348-26-000021.md) | [1.51](/filings/0001185348-26-000028.md) |
| Basic EPS | $ per share | [(0.31)](/filings/0001185348-24-000052.md) | not reported | [0.09](/filings/0001185348-25-000012.md) | [0.55](/filings/0001185348-25-000022.md) | [0.69](/filings/0001185348-25-000043.md) | not reported | [0.09](/filings/0001185348-26-000021.md) | [1.08](/filings/0001185348-26-000028.md) | [(10.43)](/filings/0001185348-25-000043.md) | not reported | [0.74](/filings/0001185348-26-000021.md) | [1.52](/filings/0001185348-26-000028.md) |

- Revenue: us-gaap:Revenues
- Research and development: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [105](/filings/0001185348-24-000052.md) | [113](/filings/0001185348-26-000006.md) | [108](/filings/0001185348-25-000012.md) | [119](/filings/0001185348-25-000022.md) | [141](/filings/0001185348-25-000043.md) | [106](/filings/0001185348-26-000006.md) | [129](/filings/0001185348-26-000021.md) | [132](/filings/0001185348-26-000028.md) | [107](/filings/0001185348-25-000043.md) | [104](/filings/0001185348-26-000028.md) | [125](/filings/0001185348-26-000021.md) | [132](/filings/0001185348-26-000028.md) |
| Total assets | $m | [4,330](/filings/0001185348-23-000037.md) | [4,525](/filings/0001185348-25-000006.md) | [4,482](/filings/0001185348-24-000026.md) | [4,662](/filings/0001185348-24-000043.md) | [4,936](/filings/0001185348-24-000052.md) | [4,931](/filings/0001185348-26-000006.md) | [5,148](/filings/0001185348-25-000012.md) | [5,435](/filings/0001185348-25-000022.md) | [4,999](/filings/0001185348-25-000043.md) | [5,103](/filings/0001185348-26-000028.md) | [5,207](/filings/0001185348-26-000021.md) | [5,239](/filings/0001185348-26-000028.md) |
| Total liabilities | $m | [3,140](/filings/0001185348-23-000037.md) | [3,286](/filings/0001185348-25-000006.md) | [3,286](/filings/0001185348-24-000026.md) | [3,459](/filings/0001185348-24-000043.md) | [3,654](/filings/0001185348-24-000052.md) | [3,738](/filings/0001185348-26-000006.md) | [3,868](/filings/0001185348-25-000012.md) | [4,038](/filings/0001185348-25-000022.md) | [4,015](/filings/0001185348-25-000043.md) | [4,063](/filings/0001185348-26-000028.md) | [4,138](/filings/0001185348-26-000021.md) | [4,126](/filings/0001185348-26-000028.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [1,116](/filings/0001185348-23-000037.md) | [1,167](/filings/0001185348-25-000006.md) | [1,129](/filings/0001185348-24-000026.md) | [1,145](/filings/0001185348-24-000043.md) | [1,219](/filings/0001185348-24-000052.md) | [1,135](/filings/0001185348-26-000006.md) | [1,219](/filings/0001185348-25-000012.md) | [1,337](/filings/0001185348-25-000022.md) | [928](/filings/0001185348-25-000043.md) | [980](/filings/0001185348-26-000028.md) | [1,002](/filings/0001185348-26-000021.md) | [1,045](/filings/0001185348-26-000028.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(37.4) d](/filings/0001185348-24-000052.md) | [20.7 d](/filings/0001185348-26-000006.md) | [(73.0)](/filings/0001185348-25-000012.md) | [(29.5) d](/filings/0001185348-25-000022.md) | [(35.0) d](/filings/0001185348-25-000043.md) | [42.9 d](/filings/0001185348-26-000006.md) | [(52.6)](/filings/0001185348-26-000021.md) | [(12.9) d](/filings/0001185348-26-000028.md) | [(10.1) d](/filings/0001185348-25-000043.md) | [(9.9) d](/filings/0001185348-26-000006.md) | [24.9](/filings/0001185348-26-000021.md) | [(36.3) d](/filings/0001185348-26-000028.md) |
| Capital expenditure | $m | [1.2 d](/filings/0001185348-24-000052.md) | [0.6 d](/filings/0001185348-26-000006.md) | [0.5](/filings/0001185348-25-000012.md) | [1.3 d](/filings/0001185348-25-000022.md) | [1.0 d](/filings/0001185348-25-000043.md) | [1.2 d](/filings/0001185348-26-000006.md) | [0.9](/filings/0001185348-26-000021.md) | [1.3 d](/filings/0001185348-26-000028.md) | [1.2 d](/filings/0001185348-25-000043.md) | [1.4 d](/filings/0001185348-26-000006.md) | [1.4](/filings/0001185348-26-000021.md) | [2.4 d](/filings/0001185348-26-000028.md) |
| Share repurchases | $m | [0.0 d](/filings/0001185348-23-000037.md) | [0.0 d](/filings/0001185348-26-000006.md) | not reported | not reported | [0.0 d](/filings/0001185348-25-000043.md) | [0.0 d](/filings/0001185348-26-000006.md) | [0.0](/filings/0001185348-26-000021.md) | [10.0 d](/filings/0001185348-26-000028.md) | [0.0 d](/filings/0001185348-25-000043.md) | [10.0 d](/filings/0001185348-26-000006.md) | [10.0](/filings/0001185348-26-000021.md) | [10.0 d](/filings/0001185348-26-000028.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q1 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [39.2](/filings/0001185348-23-000037.md) | [39.0](/filings/0001185348-24-000026.md) | [39.2](/filings/0001185348-24-000043.md) | [39.2](/filings/0001185348-24-000052.md) | [39.4](/filings/0001185348-25-000012.md) | [39.5](/filings/0001185348-25-000022.md) | [39.5](/filings/0001185348-25-000043.md) | [39.7](/filings/0001185348-26-000021.md) | [39.4](/filings/0001185348-26-000028.md) | [39.1](/filings/0001185348-25-000043.md) | [38.5](/filings/0001185348-26-000021.md) | [38.3](/filings/0001185348-26-000028.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 37,648,006 at 2026-07-31, from the cover of the [10-Q filed 2026-08-07](/filings/0001185348-26-000028.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:35 ET. No prices; not investment advice.